Anti-ALOXE3抗体

Cat. Number:

Anti-ALOXE3抗体KL-7856R

Quantity size:

0.2ml

Concentration:

1mg/ml   Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Background:

Introduces molecularAnti-ALOXE3抗体 oxygen into polyunsaturated fatty acids. Exact substrate is not known. Tissue specificity:Predominantly expressed in skin. Involvement in diseaseDefects in ALOXE3 are a cause of non-bullous congenital ichthyosiform erythroderma (NCIE). NCIE is a non-bullous ichthyosis, a skin disorder characterized by abnormal cornification of the epidermis. Most affected individuals are born with a tight, shiny, translucent covering called collodion membrane. The collodion membrane subsequently evolves into generalized scaling and intense redness of the skin. Clinical features are milder than in lamellar ichthyoses and demonstrate a greater variability in the intensity of erythema, size and type of scales. In contrast to lamellar ichthyoses, scales are usually white, fine and powdery, and palms and soles are severely affected. Patients suffer from palmoplantar keratoderma,Anti-ALOXE3抗体 often with painful fissures, digital contractures, and loss of pulp volume.

Also known as:

ALOXE3; Arachidonate Anti-ALOXE3抗体lipoxygenase 3; e LOX 3; E LOX; e-LOX-3; eLOX3; Epidermal lipoxygenase; Epidermis-type lipoxygenase 3; Lipoxygenase 3; LOXE3_HUMAN.

Specificity:

Storage:

Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).

Application:

WB=1:100-500 Anti-ALOXE3抗体 ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  IF=1:100-500   
Not yet tested in other applications. 
Optimal working dilutions must be determined by the end user.